Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Biotech A/S announced that the FDA has granted fast track designation for their personalized cancer therapy, EVX-01, in combination with KEYTRUDA® for patients with metastatic melanoma.
[Evaxion Biotech A/S]
Press Release
spot_img

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News